<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="/home/ambarish123/ocimum1/PMC5806308/results/search/drugs/results.xml">
   <result pre="cells. The dilutions of the extracts were prepared with 5%" exact="dimethyl sulfoxide" post="(DMSO) solution (D8418-500 mL ® Sigma Aldrich). This concentration"/>
   <result pre="interference by the concentration of DMSO. Positive controls such as" exact="amikacin" post="(4 mg/L) and nystatin (2 mg/mL), control of culture"/>
   <result pre="of DMSO. Positive controls such as amikacin (4 mg/L) and" exact="nystatin" post="(2 mg/mL), control of culture medium, color control of"/>
   <result pre="10 μl of MTT solution (5 mg/ml in RPMI-1640 without" exact="phenol" post="red, Sigma Aldrich®) was added to each well, and"/>
   <result pre="therefore different cell wall chemistry. The positive controls, amikacin, and" exact="nystatin" post="showed an antimicrobial effect at 4 mg/L and 2"/>
   <result pre="with intrinsic reductive potential such as some flavonoids, phytoestrogens and" exact="ascorbic acid" post="might lead to false positives in the MTT assay,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/home/ambarish123/ocimum1/PMC5824918/results/search/drugs/results.xml">
   <result pre="was found to be regulated by methyl jasmonate (MeJA) and" exact="salicylic acid" post="(SA) as exhibited by the exogenous supplementation studies. A"/>
   <result pre="and 500 µM), ( C) in response to different strength of" exact="salicylic acid" post="(0, 10, 50, 100 and 500 µM), ( D) on"/>
   <result pre="somnifera A. annua was selected as it contains important sesquiterpenoidal" exact="artemisinin" post="as well as essential oil. Expression study revealed an"/>
   <result pre="of untransformed control and over-expressed tissues showed an increase in" exact="artemisinin" post="content by 7.4% (Fig. 6C). Figure 6 Expression profiles"/>
   <result pre="total essential oil content (mg/g FW g −1), ( C)" exact="artemisinin" post="content (µg g −1); and W. somnifera ( D)"/>
   <result pre="of inhibitors on gene expression and secondary metabolite content Inhibitors" exact="mevastatin" post="and pravastatin were used to evaluate the blocking of"/>
   <result pre="on gene expression and secondary metabolite content Inhibitors mevastatin and" exact="pravastatin" post="were used to evaluate the blocking of the pathway"/>
   <result pre="ox- transformed tissue without inhibitor treatment, Control + P- untransformed tissue with" exact="pravastatin" post="treatment, Vector control + P- vector transformed tissue with pravastatin treatment,"/>
   <result pre="tissue with pravastatin treatment, Vector control + P- vector transformed tissue with" exact="pravastatin" post="treatment, HMGR ox + P- transformed tissue with pravastatin treatment, Control + M-"/>
   <result pre="transformed tissue with pravastatin treatment, HMGR ox + P- transformed tissue with" exact="pravastatin" post="treatment, Control + M- untransformed tissue with mevastatin treatment, Vector control + M-"/>
   <result pre="ox + P- transformed tissue with pravastatin treatment, Control + M- untransformed tissue with" exact="mevastatin" post="treatment, Vector control + M- vector transformed tissue with mevastatin treatment"/>
   <result pre="tissue with mevastatin treatment, Vector control + M- vector transformed tissue with" exact="mevastatin" post="treatment and HMGR ox + M- transformed tissue with mevastatin treatment."/>
   <result pre="tissue with mevastatin treatment and HMGR ox + M- transformed tissue with" exact="mevastatin" post="treatment. Similar pattern was observed in A. annua, where"/>
   <result pre="lowered the relative expression to 0.3 and 0.4 fold for" exact="pravastatin" post="and mevastatin treated and control lines, respectively (Fig. 8A)"/>
   <result pre="relative expression to 0.3 and 0.4 fold for pravastatin and" exact="mevastatin" post="treated and control lines, respectively (Fig. 8A) and a"/>
   <result pre="8A) and a reduction in total essential oil content and" exact="artemisinin" post="was also observed (Fig. 8B,C). Comparative analysis of treated"/>
   <result pre="untransformed control. However, the secondary metabolites i.e. essential oil and" exact="artemisinin" post="content declined, revealing the alterations in artemisinin were more"/>
   <result pre="essential oil and artemisinin content declined, revealing the alterations in" exact="artemisinin" post="were more prominent indicating preference of MVA pathway participation"/>
   <result pre="ox- transformed tissue without inhibitor treatment, Control + P- untransformed tissue with" exact="pravastatin" post="treatment, Vector control + P- vector transformed tissue with pravastatin treatment,"/>
   <result pre="tissue with pravastatin treatment, Vector control + P- vector transformed tissue with" exact="pravastatin" post="treatment, HMGR ox + P- transformed tissue with pravastatin treatment, Control + M-"/>
   <result pre="transformed tissue with pravastatin treatment, HMGR ox + P- transformed tissue with" exact="pravastatin" post="treatment, Control + M- untransformed tissue with mevastatin treatment, Vector control + M-"/>
   <result pre="ox + P- transformed tissue with pravastatin treatment, Control + M- untransformed tissue with" exact="mevastatin" post="treatment, Vector control + M- vector transformed tissue with mevastatin treatment"/>
   <result pre="tissue with mevastatin treatment, Vector control + M- vector transformed tissue with" exact="mevastatin" post="treatment and HMGR ox + M- transformed tissue with mevastatin treatment."/>
   <result pre="tissue with mevastatin treatment and HMGR ox + M- transformed tissue with" exact="mevastatin" post="treatment. W. somnifera was also influenced by the inhibitory"/>
   <result pre="also influenced by the inhibitory action of inhibitors. Pravastatin and" exact="mevastatin" post="treatment reduced the gene expression to 0.3–0.6 folds in"/>
   <result pre="(ECS) of A. annua in N. benthamiana, intermediate enzymes of" exact="artemisinin" post="biosynthesis pathway was reported to show remarkable increase in"/>
   <result pre="biosynthesis pathway was reported to show remarkable increase in the" exact="artemisinin" post="production 41 . The percentage of the essential oil"/>
   <result pre="other family. A. annua is rich in essential oils and" exact="artemisinin" post="content and over-expression of HMGR increased the total essential"/>
   <result pre="HMGR increased the total essential oil content by 15% while" exact="artemisinin" post="content by 7.4%. Our result was in consensus with"/>
   <result pre="of plant with Catharanthus roseus (L.) HMGR could drive the" exact="artemisinin" post="content 50 . These findings further proved that HMGR"/>
   <result pre="were also treated with NaCl (0, 50, 100 and 250 mM)," exact="salicylic acid" post="and methyl jasmonate (0, 10, 50, 100 and 500 µM),"/>
   <result pre="of control and transiently transformed plants were treated with both" exact="mevastatin" post="and pravastatin individually for 24 hrs followed by various"/>
   <result pre="and transiently transformed plants were treated with both mevastatin and" exact="pravastatin" post="individually for 24 hrs followed by various analysis. Secondary"/>
   <result pre="GM Overexpression of the HMG-CoA reductase gene leads to enhanced" exact="artemisinin" post="biosynthesis in transgenic Artemisia annua plants Planta Med. 2009"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/home/ambarish123/ocimum1/PMC5987647/results/search/drugs/results.xml">
   <result pre="of hydro-methanol alone served as vehicle control. The MNTCs of" exact="amantadine" post="and oseltamivir antiviral drugs were determined by inoculating 5.33,"/>
   <result pre="alone served as vehicle control. The MNTCs of amantadine and" exact="oseltamivir" post="antiviral drugs were determined by inoculating 5.33, 8 and"/>
   <result pre="37 °C for 2 h. The drug control group included" exact="amantadine" post="hydrochloride (MNTC-16 μg/0.1 ml) incubated with 500 EID 50/0.1"/>
   <result pre="drug is poor [ 32]. In the drug control group," exact="oseltamivir" post="(MNTC–2.66 μg/0.1 ml) was injected through albumen route 2"/>
   <result pre="for 72 h (Fig. 1). In the drug control group," exact="amantadine" post="hydrochloride (MNTC-16 μg/0.1 ml) was given through allantoic cavity"/>
   <result pre="dose of 16 μg/0.1 ml and 2.66 μg/0.1 ml for" exact="amantadine" post="hydrochloride and oseltamivir, respectively and thus have been used"/>
   <result pre="However, polyphenol ocimum , polyphenol acacia and the drug control" exact="amantadine" post="treatment groups did not show any HA titer even"/>
   <result pre="(24, 48 and 72 h) post-inoculation. The drug control group" exact="oseltamivir" post="also showed absence of HA titer indicating no viral"/>
   <result pre="be the reason for delayed effect. Variable bioavailability of drugs," exact="oseltamivir" post="and ribavirin via albumin route has been established previously"/>
   <result pre="reason for delayed effect. Variable bioavailability of drugs, oseltamivir and" exact="ribavirin" post="via albumin route has been established previously also ["/>
   <result pre="to study the susceptibility of avian influenza H9N2 viruses to" exact="oseltamivir" post="carboxylate J Virol Methods 2015 224 67 72 10.1016/j.jviromet.2015.08.009"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/home/ambarish123/ocimum1/PMC6093078/results/search/drugs/results.xml">
   <result pre="the bioavailability of the active component. A sodium salt of" exact="alginic acid" post="or sodium alginate is able to form a cross-linked"/>
   <result pre="et al. Formulation and characterization of calcium alginate beads containing" exact="ampicillin" post="Pharmaceutical Development and Technology 1998 3 2 193 198"/>
   <result pre="Kumar D. Das M. Preparation and in vitro characterization of" exact="diltiazem" post="hydrochloride loaded alginate microspheres Pharmaceutical Development and Technology 2009"/>
   <result pre="S. Montaseri H. Tafaghodi M. Preparation and characterization of biodegradable" exact="paclitaxel" post="loaded alginate microparticles for pulmonary delivery Colloids and Surfaces"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/home/ambarish123/ocimum1/PMC6200556/results/search/drugs/results.xml">
   <result pre="some drugs have already licensed for many years, such as" exact="levodopa" post="in Parkinson’s disease [ 3] and acetylcholinesterase inhibitors in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="/home/ambarish123/ocimum1/PMC6239295/results/search/drugs/results.xml">
   <result pre="plastid peptides, OsaTPS-c and–e lack twin-arginine residues but consist only" exact="tryptophan" post="residue. NSE/DTE motifs were continuously seen conserved except OsaTPS-c"/>
   <result pre="motif does not have the twin-arginine residue but have conserved" exact="tryptophan" post="residues. In TPS-a, subfamily, members of O. sanctum either"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
